Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq
Location
2401 4 Th Ave., Suite 1050, Seattle, WA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 158 % -34.1%
Debt-to-equity 285 % +127%
Return On Equity -676 % -154%
Return On Assets -176 % -48.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.29M shares -65.1%
Common Stock, Shares, Outstanding 3.22M shares -21%
Entity Public Float 1.2M USD -89.1%
Common Stock, Value, Issued 99K USD +43.5%
Weighted Average Number of Shares Outstanding, Basic 738K shares -84.5%
Weighted Average Number of Shares Outstanding, Diluted 738K shares -84.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.9M USD -6.24%
General and Administrative Expense 10.4M USD -6.52%
Operating Income (Loss) -24.3M USD +6.36%
Net Income (Loss) Attributable to Parent -24M USD +3.72%
Earnings Per Share, Basic 1.51K USD/shares
Earnings Per Share, Diluted 1.51K USD/shares +99.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.41M USD +16.7%
Other Assets, Current 82K USD -88.5%
Assets, Current 11.1M USD +15.7%
Property, Plant and Equipment, Net 432K USD -38%
Operating Lease, Right-of-Use Asset 4.11M USD -11.5%
Assets 15.6M USD +4.71%
Employee-related Liabilities, Current 1.04M USD +16.6%
Liabilities, Current 4.89M USD -9.74%
Operating Lease, Liability, Noncurrent 4.21M USD -15.8%
Other Liabilities, Noncurrent 0 USD
Liabilities 9.1M USD -13%
Retained Earnings (Accumulated Deficit) -260M USD -10.2%
Stockholders' Equity Attributable to Parent 6.52M USD +46.2%
Liabilities and Equity 15.6M USD +4.71%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.58M USD +1.14%
Net Cash Provided by (Used in) Financing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 3.22M shares -21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.58M USD +1.19%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD -30.1%
Deferred Tax Assets, Valuation Allowance 49.2M USD -7.59%
Deferred Tax Assets, Gross 50.1M USD -7.64%
Operating Lease, Liability 5.4M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 7.34M USD -15.8%
Property, Plant and Equipment, Gross 14.5M USD 0%
Operating Lease, Liability, Current 800K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.94M USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.38M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 344K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 61K USD -42.5%
Deferred Tax Assets, Net of Valuation Allowance 922K USD -10.2%
Share-based Payment Arrangement, Expense 530K USD -73.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%